Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...

Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the ...

A new dashboard by the ALS Association offers free and open access to real-world data from more than 4,000 people affected by ...

With the industry’s largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation ...

Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...

Ancora Heart today announced two-year results from an analysis of early clinical studies evaluating its AccuCinch system.

Fulgent Genetics (FLGT) announced preliminary clinical data as of September 25, the preliminary data cutoff from its ongoing phase 2 clinical ...

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

Every breakthrough in modern medicine begins not with a marketing campaign or a press release, but with data — precise, ...

The termination of thousands of federal grants that fund clinical trials threatens to reverse substantial progress in ...